课题基金 / 基金详情

CLINICAL TRIAL: PHASE I/II MULTICENTER,OPEN LABEL,NONCOMPARITIVE STUDY OF HIV AF

CLINICAL TRIAL: PHASE I/II MULTICENTER,OPEN LABEL,NONCOMPARITIVE STUDY OF HIV AF
临床试验:I/II 期多中心、开放标签、HIV AF 非比较研究
批准号:
7950832
负责人:
Sharon A Nachman
金额:
$1.92万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-12-01 至 2009-11-30

项目摘要

项目成果

Sharon A Nachman的其他基金

相似基金

相关文献

中文摘要
翻译
该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者(PI)可能从另一个NIH来源获得主要资金, 因此可以在其他CRISP条目中表示。列出的机构是 中心,不一定是研究者的机构。 1. 在第I阶段,评估雷特格韦在HIV感染儿童和青少年中的短期安全性和耐受性,将其添加到初始稳定背景治疗 * 中,然后在年龄组=2至<6岁,=6至<12岁和=12至<19岁的儿童和青少年中进行优化。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. 1. In Stage I, to evaluate the short term safety and tolerability of raltegravir, in HIV infected children and adolescents, added to an initial stable background therapy* which will then be optimized in children and adolescents in the age groups of =2 to <6, =6 to <12 and =12 to <19 years.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the US
  • 批准号:
    10174121
  • 项目类别:
  • 资助金额:
    $94.26万
  • 财政年份:
    2020
  • 负责人:
    Sharon A Nachman
  • 依托单位:
SURVEILLANCE MONITORING FOR ART TOXICITIES
CLINICAL TRIAL: PHASE I/II STUDY OF SAFETY AND IMMUNOGENICITY OF QUADRIVALENT ME
CLINICAL TRIAL: PSYCHIATRIC CO-MORBIDITY IN PERINATALLY HIV-INFECTED CHILDREN AN
海外基金